(VIANEWS) – Eli Lilly and Company (LLY), MGP Ingredients (MGPI), Terreno Realty Corporation (TRNO) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Eli Lilly and Company (LLY)
14.7% sales growth and 54.79% return on equity
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Earnings Per Share
As for profitability, Eli Lilly and Company has a trailing twelve months EPS of $6.29.
PE Ratio
Eli Lilly and Company has a trailing twelve months price to earnings ratio of 73.72. Meaning, the purchaser of the share is investing $73.72 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 54.79%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Eli Lilly and Company’s EBITDA is 16.28.
Dividend Yield
As maintained by Morningstar, Inc., the next dividend payment is on May 11, 2023, the estimated forward annual dividend rate is 4.52 and the estimated forward annual dividend yield is 0.99%.
Moving Average
Eli Lilly and Company’s value is higher than its 50-day moving average of $423.11 and way higher than its 200-day moving average of $362.83.
2. MGP Ingredients (MGPI)
13.8% sales growth and 14.09% return on equity
MGP Ingredients, Inc., together with its subsidiaries, produces and supplies distilled spirits, and specialty wheat proteins and starch food ingredients. It operates through two segments, Distillery Products and Ingredient Solutions. The Distillery Products segment provides food grade alcohol for beverage applications that include bourbon and rye whiskeys, as well as grain neutral spirits, including vodka and gin; and food grade industrial alcohol, which is used as an ingredient in foods, personal care products, cleaning solutions, pharmaceuticals, and various other products. This segment also provides fuel grade alcohol for blending with gasoline; distillers feed and related co-products, such as distillers feed and corn oil; and warehouse services, including barrel put away, storage, and retrieval services, as well as blending services. The Ingredient Solutions segment provides specialty wheat starches for food applications under the Fibersym Resistant Starch, FiberRite RW Resistant Starch, Pregel Instant Starch, and Midsol Cook-up Starch names; specialty wheat proteins for food applications under the Arise and Proterra names; gluten free textured pea proteins; commodity wheat starch for food and non-food applications; and commodity wheat proteins. The company sells its products directly or through distributors to manufacturers and processors of finished packaged goods or to bakeries primarily in the United States, Japan, Thailand, Mexico, and Canada. MGP Ingredients, Inc. was founded in 1941 and is headquartered in Atchison, Kansas.
Earnings Per Share
As for profitability, MGP Ingredients has a trailing twelve months EPS of $4.62.
PE Ratio
MGP Ingredients has a trailing twelve months price to earnings ratio of 22.32. Meaning, the purchaser of the share is investing $22.32 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 14.09%.
3. Terreno Realty Corporation (TRNO)
13.6% sales growth and 8.67% return on equity
Terreno Realty Corporation and together with its subsidiaries, the “Company”) acquires, owns and operates industrial real estate in six major coastal U.S. markets: Los Angeles, Northern New Jersey/New York City, San Francisco Bay Area, Seattle, Miami, and Washington, D.C. All square feet, acres, occupancy and number of properties disclosed in these condensed notes to the consolidated financial statements are unaudited. As of September 30, 2020, the Company owned 219 buildings aggregating approximately 13.1 million square feet, 22 improved land parcels consisting of approximately 85.0 acres and one property under redevelopment expected to contain approximately 0.2 million square feet upon completion. The Company is an internally managed Maryland corporation and elected to be taxed as a real estate investment trust (“REIT”) under Sections 856 through 860 of the Internal Revenue Code of 1986, as amended (the “Code”), commencing with its taxable year ended December 31, 2010.
Earnings Per Share
As for profitability, Terreno Realty Corporation has a trailing twelve months EPS of $2.64.
PE Ratio
Terreno Realty Corporation has a trailing twelve months price to earnings ratio of 22.2. Meaning, the purchaser of the share is investing $22.2 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.67%.
Dividend Yield
As stated by Morningstar, Inc., the next dividend payment is on Jun 28, 2023, the estimated forward annual dividend rate is 1.6 and the estimated forward annual dividend yield is 2.58%.
Sales Growth
Terreno Realty Corporation’s sales growth is 19.9% for the ongoing quarter and 13.6% for the next.
Yearly Top and Bottom Value
Terreno Realty Corporation’s stock is valued at $58.60 at 16:22 EST, way under its 52-week high of $67.03 and way higher than its 52-week low of $50.36.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Terreno Realty Corporation’s EBITDA is 20.47.
4. Transcat (TRNS)
11.5% sales growth and 11.5% return on equity
Transcat, Inc. provides calibration and laboratory instrument services in the United States, Canada, and internationally. It operates in two segments, Service and Distribution. The Service segment offers calibration, repair, inspection, analytical qualification, preventative maintenance, consulting, and other related services. This segment also provides CalTrak, a proprietary document and asset management software that is used to integrate and manage the workflow of its calibration service centers and customers' assets; and Compliance, Control and Cost, an online customer portal that provides its customers with web-based asset management capability, as well as a safe and secure off-site archive of calibration and other service records. The Distribution segment sells and rents test, measurement, and control instruments for customers' test and measurement instrumentation needs, as well as value added services, such as calibration/certification of equipment purchase, equipment rental, used equipment for sale, and equipment kitting. This segment markets and sells its products through website, digital and print advertising, proactive outbound sales, and an inbound call center. The company provides services and products to highly regulated industries, principally life science, which includes companies in the pharmaceutical, biotechnology, medical device, and other FDA-regulated industries; and additional industries, including aerospace and defense industrial manufacturing, oil and gas and alternative energy, and other industries that require accuracy in processes and confirmation of the capabilities of their equipment. Transcat, Inc. was incorporated in 1964 and is headquartered in Rochester, New York.
Earnings Per Share
As for profitability, Transcat has a trailing twelve months EPS of $1.38.
PE Ratio
Transcat has a trailing twelve months price to earnings ratio of 65.53. Meaning, the purchaser of the share is investing $65.53 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 11.5%.
5. CVS Health (CVS)
7.6% sales growth and 5.42% return on equity
CVS Health Corporation provides health services in the United States. It operates through Health Care Benefits, Pharmacy Services, and Retail/LTC segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services. It serves employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers, governmental units, government-sponsored plans, labor groups, and expatriates. The Pharmacy Services segment offers pharmacy benefit management solutions, including plan design and administration, formulary management, retail pharmacy network management, mail order pharmacy, specialty pharmacy and infusion, clinical, and disease and medical spend management services. It serves employers, insurance companies, unions, government employee groups, health plans, prescription drug plans, Medicaid managed care plans, plans offered on public health insurance and private health insurance exchanges, other sponsors of health benefit plans, and individuals. This segment operates retail specialty pharmacy stores; and specialty mail-order, mail-order dispensing, and compounding pharmacies, as well as branches for infusion and enteral nutrition services. The Retail/LTC segment sells prescription and over-the-counter drugs, consumer health and beauty products, and personal care products; and provides health care services through its MinuteClinic walk-in medical clinics. This segment also distributes prescription drugs; and provides related pharmacy consulting and other ancillary services to care facilities and other care settings. The company was formerly known as CVS Caremark Corporation and changed its name to CVS Health Corporation in September 2014. CVS Health Corporation was incorporated in 1996 and is headquartered in Woonsocket, Rhode Island.
Earnings Per Share
As for profitability, CVS Health has a trailing twelve months EPS of $3.01.
PE Ratio
CVS Health has a trailing twelve months price to earnings ratio of 22.86. Meaning, the purchaser of the share is investing $22.86 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.42%.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter is a negative 11.3% and positive 4.8% for the next.
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on Apr 19, 2023, the estimated forward annual dividend rate is 2.42 and the estimated forward annual dividend yield is 3.49%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 10.8%, now sitting on 329.92B for the twelve trailing months.
Yearly Top and Bottom Value
CVS Health’s stock is valued at $68.81 at 16:22 EST, way under its 52-week high of $107.26 and higher than its 52-week low of $66.34.
